Researchers at University College London have unveiled a drug that shows promise in treating microbial keratitis, a rare but serious eye infection affecting the cornea. The findings were published in PubMed, marking a step forward in understanding how this condition can be managed more effectively.
Bacterial keratitis is an acute inflammation of the cornea that brings pain, swelling, and sensitivity to light. If not treated promptly, it can impair vision and even lead to permanent blindness. The infection arises when pathogenic microbes colonize the corneal surface and disrupt the protective epithelial barrier. Those who wear contact lenses frequently are at higher risk, making awareness and early care crucial for this group.
The team tested a low-dose formulation of polyhexanide at 0.02 percent. This compound, first used in the 1990s for related eye conditions, now benefits from modern manufacturing advances that reduce formulation errors and improve safety and effectiveness in clinical use.
In safety evaluations conducted with healthy volunteers, the drug demonstrated a favorable safety profile. Its therapeutic potential was then assessed in patients with bacterial keratitis, where improvements were observed in the majority of cases. In a clinical trial, noticeable progress occurred in 110 of 127 participants, signaling meaningful benefit for those affected by this infection.
Researchers anticipate that the treatment could become a standard option in clinical practice, potentially lowering the need for surgical intervention in severe cases and mitigating serious complications linked to bacterial keratitis. The ongoing work aims to confirm results across broader populations and real-world settings, strengthening confidence among clinicians and patients alike.
In related genetic research, a gene linked to a specific eye disease was identified, offering new directions for understanding susceptibility and potential prevention strategies. This discovery adds a broader context to the fight against corneal infections and related ocular conditions, underscoring the value of continued investment in eye health research for communities across North America and beyond.